SCLX at a glance
The past year
Chart−94.2% $0.64, close Nov 17
- From the highest close
- −95.4%
- Vs the 200-day average
- −87.2%
Short interest
History132,205 shares
- Of shares outstanding
- 1.56%
- Since the last report
- −10.9%
- Days to cover
- 3.4 days
- Settled
- Oct 30, 2026
Insider buying, 7 days
FilingsNone filed this week
- Form 4s filed
- Nov 11 – Nov 17
Understand the Business
Why the Stock Moved
Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.
SCLX price history
Loading recent earnings…
Investment thesis
What must happen next
Scilex's revenue is produced by an asset‑light/licensing or low‑COGS commercialization model so the business can sustain very high gross margins and rapidly convert additional sales into gross profit.StrengtheningMateriality: High
gross_profit of $125.8M on revenue $136.4M in FY2025 (~>90% gross margin). If true, incremental revenue should generate high incremental cash and make scaling to profitability easier; if false, rising COGS or pricing pressure will compress margins and make profitability unattainable without large revenue gains.
Watch: loss of exclusive distribution or licensing terms that shifts sales to low‑margin direct product manufacturing.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
gross_profit of $125.8M on revenue $136.4M in FY2025 (~>90% gross margin).
Open source ↗Revenue growth is lumpy and driven by a small set of commercial products, partner agreements and milestone/licensing receipts rather than broad, repeatable prescription volume, so topline can swing materially year‑to‑year.HoldingMateriality: High
revenue jumped from $46.7M (FY2023) to $184.1M (FY2024) and then declined to $136.4M (FY2025), showing large year-to-year swings. If revenue stays lumpy and partner‑concentrated, investors should expect volatile results, making the path to sustained profitability and valuation multiple expansion uncertain; conversely, durability and diversification would de‑risk the stock.
Watch: loss or non‑renewal of a major distribution/license agreement or a partner failing to meet sales/marketing commitments.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
revenue jumped from $46.7M (FY2023) to $184.1M (FY2024) and then declined to $136.4M (FY2025), showing large year-to-year swings.
Open source ↗Given very large operating losses relative to cash on hand, Scilex will need external financing or asset monetization unless it sharply reduces operating cash burn or secures material milestone/license receipts.StrengtheningMateriality: Medium
cash and cash equivalents of $4.955M at 2025 year end. If Scilex cannot access non‑dilutive cash or cut burn, shareholders will face dilution or value‑destructive asset sales; if it can, the business can pursue commercialization and defend gross margins.
Watch: ability to raise debt or equity on reasonable terms or to secure non‑dilutive milestone payments from partners.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
cash and cash equivalents of $4.955M at 2025 year end.
Open source ↗Reported operating cash flow has turned positive recently but remains small and volatile, so internal cash generation is currently insufficient to cover reported operating losses and fund growth without external capital or recurring revenue expansion.HoldingMateriality: Medium
operating_cash_flow of $19.349M in FY2024 and $3.816M in FY2025 (positive but falling). Sustained, growing operating cash flow would reduce financing risk and validate the business model; continued volatility or decline would keep the company dependent on external financing.
Watch: one‑time timing effects or milestone receipts driving temporary positive cash flow rather than recurring operations.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
operating_cash_flow of $19.349M in FY2024 and $3.816M in FY2025 (positive but falling).
Open source ↗
Full investment case & evidence
Loading the original research archive…
Original research
Scilex's revenue is produced by an asset‑light/licensing or low‑COGS commercialization model so the business can sustain very high gross margins and rapidly convert additional sales into gross profit. If true, incremental revenue should generate high incremental cash and make scaling to profitability easier; if false, rising COGS or pricing pressure will compress margins and make profitability unattainable without large revenue gains.
Revenue growth is lumpy and driven by a small set of commercial products, partner agreements and milestone/licensing receipts rather than broad, repeatable prescription volume, so topline can swing materially year‑to‑year. If revenue stays lumpy and partner‑concentrated, investors should expect volatile results, making the path to sustained profitability and valuation multiple expansion uncertain; conversely, durability and diversification would de‑risk the stock.
Given very large operating losses relative to cash on hand, Scilex will need external financing or asset monetization unless it sharply reduces operating cash burn or secures material milestone/license receipts. If Scilex cannot access non‑dilutive cash or cut burn, shareholders will face dilution or value‑destructive asset sales; if it can, the business can pursue commercialization and defend gross margins.
Reported operating cash flow has turned positive recently but remains small and volatile, so internal cash generation is currently insufficient to cover reported operating losses and fund growth without external capital or recurring revenue expansion. Sustained, growing operating cash flow would reduce financing risk and validate the business model; continued volatility or decline would keep the company dependent on external financing.
All standing thesis claims
Original report summary
Scilex can build value by acquiring and commercializing non‑opioid pain products that generate very high gross margins, but value depends on converting lumpy, partner‑driven revenue into recurring, self‑funding cash flow while repairing a stretched.
Bull case and bear case
Bull case and bear case for Scilex Holding Co
Where the evidence on Scilex Holding Co stands: Holding on the latest evidence (Nov 18, 2026). Of its 4 thesis points, 2 strengthening and 2 holding.
Bull case: what the evidence supports
Scilex's revenue is produced by an asset‑light/licensing or low‑COGS commercialization model so the business can sustain very high gross margins and rapidly convert additional sales into gross profit.
Revenue growth is lumpy and driven by a small set of commercial products, partner agreements and milestone/licensing receipts rather than broad, repeatable prescription volume, so topline can swing materially year‑to‑year.
Given very large operating losses relative to cash on hand, Scilex will need external financing or asset monetization unless it sharply reduces operating cash burn or secures material milestone/license receipts.
Reported operating cash flow has turned positive recently but remains small and volatile, so internal cash generation is currently insufficient to cover reported operating losses and fund growth without external capital or recurring revenue expansion.
Bear case: what would count against it
loss of exclusive distribution or licensing terms that shifts sales to low‑margin direct product manufacturing.
loss or non‑renewal of a major distribution/license agreement or a partner failing to meet sales/marketing commitments.
ability to raise debt or equity on reasonable terms or to secure non‑dilutive milestone payments from partners.
Thesis-Break Engine
Thesis-break watch · Scilex Holding Co
Loading the break-condition record for Scilex Holding Co.
MARKET + FINANCIAL SNAPSHOT
The numbers behind the thesis
What Changed
- MixedChanged certifying accountant.
Scilex Holding Co filed an SEC 8-K on 2026-11-17: Changed certifying accountant. It is a dated development that tests the current thesis.
- MixedEntered a material definitive agreement.
Scilex Holding Co filed an SEC 8-K on 2026-09-29: Entered a material definitive agreement. It is a dated development that tests the current thesis.
- MixedEntered a material definitive agreement.
Scilex Holding Co filed an SEC 8-K on 2026-08-12: Entered a material definitive agreement. It is a dated development that tests the current thesis.
Risks / falsifiers
What could break the thesis
- loss of exclusive distribution or licensing terms that shifts sales to low‑margin direct product manufacturing.
- loss or non‑renewal of a major distribution/license agreement or a partner failing to meet sales/marketing commitments.
- ability to raise debt or equity on reasonable terms or to secure non‑dilutive milestone payments from partners.
- one‑time timing effects or milestone receipts driving temporary positive cash flow rather than recurring operations.
SCLX news
Loading headlines…
Financial statements
SCLX income statement
Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.
SCLX: quick answers
- What is SCLX's short interest?
- As of October 30, 2026, 132,205 SCLX shares were sold short, 1.56% of its shares outstanding, down 10.9% from the count before. At the stock's average daily volume that is 3.4 days to cover. FINRA publishes the count twice a month. SCLX short interest history

